Alliances
Between the Moderna and Pfizer-BioNTech COVID-19 vaccines, there are two mRNA therapeutics on the market … the only two.
The companies will harness BridGene’s IMTAC (Isobaric Mass Tagged Affinity Characterization) Chemoproteomics platform to identify targets and small molecule drug candidates.
Jerusalem’s clinical-stage pharmaceutical company Oramed Pharmaceuticals is forming a joint venture with Premas Biotech to develop novel oral COVID-19 vaccine candidates.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
Merck and Eisai announced that their combination of Merck’s checkpoint inhibitor Keytruda and Eisai’s Lenvima, a tyrosine kinase inhibitor, significantly improved progression-free survival in advanced endometrial cancer.
Anima Biotech’s strategic collaboration with Takeda Pharmaceutical, just announced today, uses its novel platform for discovery of mRNA translation modulators to discover and develop a new class of therapies for neurological diseases.
Multiple pharmaceutical companies struck large licensing deals with one another this week. Here’s a look.
It will evaluate about 440 patients and the treatments’ effect on liver fibrosis improvement and NASH resolution.
In recent years, AI-fueled drug discovery programs have risen dramatically, particularly in regard to rare diseases.
Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, has entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases.
PRESS RELEASES